Biophytis S.A. (BPTS)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Biophytis S.A. (BPTS) trades at $8.22 with AI Score 44/100 (Grade C). Biophytis S. A. is a clinical-stage biotechnology company focused on developing therapeutics for age-related diseases. Market cap: $2.61M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for BPTS: BPTS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BPTS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BPTS: the 1 perspectives are evenly split.
How is this calculated? →Biophytis S.A. (BPTS) Healthcare & Pipeline Overview
Biophytis S.A. is a clinical-stage biotechnology firm developing therapeutics for age-related degenerative diseases, primarily through its Sarconeos (BIO101) drug candidate targeting sarcopenia, Duchenne muscular dystrophy, and COVID-19-related respiratory failure, positioning it within the competitive biotechnology landscape.
What Is the Investment Thesis for BPTS?
Biophytis S.A. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's valuation is currently tied to the successful clinical development and commercialization of Sarconeos (BIO101) and Macuneos (BIO201). Key value drivers include positive clinical trial results for Sarconeos in sarcopenia, DMD, and COVID-19-related respiratory failure. The ongoing Phase 2/3 study for Sarconeos in COVID-19 patients is a critical catalyst. Failure to achieve positive clinical outcomes or secure regulatory approvals could significantly impact the company's valuation. The company's relatively small size and limited financial resources also pose risks to its long-term viability.
Based on FMP financials and quantitative analysis
BPTS Key Highlights
- Biophytis S.A. is a clinical-stage company, meaning its value is heavily dependent on successful clinical trial outcomes.
- Sarconeos (BIO101) is the lead drug candidate, targeting multiple indications including sarcopenia, Duchenne muscular dystrophy (DMD), and COVID-19-related respiratory failure.
- Macuneos (BIO201) is being developed for retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease, expanding the company's therapeutic focus.
- The company has a collaboration agreement with AFM-Telethon for the development of Sarconeos (BIO101) for the treatment of DMD.
- The company's market capitalization is $0.00B, reflecting its early stage and the inherent risks associated with biotechnology investments.
Who Are BPTS's Competitors?
BPTS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| EIGRQ Eiger BioPharmaceuticals, Inc. | $8.50 | +6.25% | $12.59M | 54 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BPTS's Key Strengths?
- Novel drug candidates targeting age-related diseases.
- Focus on biological resilience pathways.
- Collaboration with AFM-Telethon.
- Potential for orphan drug designation.
What Are BPTS's Weaknesses?
- Clinical-stage company with no approved products.
- Limited financial resources.
- High risk of clinical trial failure.
- Dependence on successful development of Sarconeos and Macuneos.
What Could Drive BPTS Stock Higher?
- Phase 3 clinical trial results for Sarconeos (BIO101) in sarcopenia.
- Regulatory approval decisions for Sarconeos (BIO101) in sarcopenia, DMD, or COVID-19-related respiratory failure.
- Enrollment and progress in clinical trials for Macuneos (BIO201) in dry AMD.
- Potential strategic partnerships with other biotechnology and pharmaceutical companies.
What Are the Key Risks for BPTS?
- Financial-distress signal — its Altman Z-Score of -13.38 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for Sarconeos (BIO101) or Macuneos (BIO201).
- Regulatory delays or rejection of marketing applications.
- Competition from established pharmaceutical companies.
- Limited financial resources and need for additional funding.
- Patent expiration and generic competition.
What Are the Growth Opportunities for BPTS?
- Sarconeos (BIO101) for Sarcopenia: The global sarcopenia market is projected to reach billions of dollars by 2030, driven by the aging population and increasing awareness of muscle loss. Positive Phase 3 trial results for Sarconeos in sarcopenia could lead to regulatory approval and commercialization, providing a significant revenue stream for Biophytis. The timeline for potential market entry is dependent on trial outcomes and regulatory review, but could be within the next 3-5 years.
- Sarconeos (BIO101) for Duchenne Muscular Dystrophy (DMD): DMD is a rare genetic disorder with limited treatment options. Sarconeos has the potential to address the underlying muscle degeneration in DMD patients. The company's collaboration with AFM-Telethon provides access to expertise and resources for DMD drug development. Market size is smaller than sarcopenia, but the unmet need and potential for orphan drug designation could provide pricing advantages.
- Sarconeos (BIO101) for COVID-19-related Respiratory Failure: The COVID-19 pandemic has created a significant need for therapies to treat severe respiratory failure. Sarconeos is currently in Phase 2/3 clinical trials for this indication. Positive results could lead to rapid regulatory approval and commercialization, providing a near-term revenue opportunity for Biophytis. However, the evolving nature of the pandemic and the emergence of new variants pose uncertainties.
- Macuneos (BIO201) for Dry Age-Related Macular Degeneration (AMD): Dry AMD is a leading cause of vision loss in the elderly. Macuneos is being developed to address the underlying retinal degeneration in dry AMD patients. The dry AMD market is large and growing, with limited treatment options available. Successful clinical development and commercialization of Macuneos could provide a significant long-term growth opportunity for Biophytis.
- Expansion of Pipeline through Strategic Partnerships: Biophytis can leverage its expertise in age-related diseases to expand its pipeline through strategic partnerships with other biotechnology and pharmaceutical companies. These partnerships could provide access to new drug candidates, technologies, and markets. The company's collaboration with AFM-Telethon demonstrates its ability to forge successful partnerships. Identifying and securing additional partnerships will be crucial for long-term growth and diversification.
What Opportunities Does BPTS Have?
- Growing market for age-related disease therapeutics.
- Potential for strategic partnerships.
- Expansion of pipeline through new drug candidates.
- Fast-track regulatory approval for certain indications.
What Threats Does BPTS Face?
- Competition from established pharmaceutical companies.
- Regulatory hurdles and delays.
- Patent expiration.
- Adverse events in clinical trials.
What Are BPTS's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Expertise in age-related diseases and biological resilience pathways.
- Clinical trial data demonstrating safety and efficacy.
- Collaboration agreements with research institutions and patient organizations.
- Potential for orphan drug designation for certain indications.
What Does BPTS Do?
Biophytis S.A., founded in 2006 and headquartered in Paris, France, is a clinical-stage biotechnology company dedicated to developing therapeutics that address age-related degenerative processes. The company's core focus lies in identifying and activating key biological resilience pathways, aiming to protect against and counteract the multiple biological and environmental stresses that contribute to age-related diseases. Their lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule currently in development for treating neuromuscular diseases such as sarcopenia and Duchenne muscular dystrophy (DMD). Sarconeos is also undergoing Phase 2/3 clinical trials for the treatment of severe respiratory failure in patients suffering from COVID-19. In addition to Sarconeos, Biophytis is developing Macuneos (BIO201), another orally administered small molecule, designed for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis collaborates with AFM-Telethon for the development of Sarconeos (BIO101) in treating DMD, highlighting their commitment to partnerships in advancing therapeutic solutions.
What Products and Services Does BPTS Offer?
- Develop therapeutics for age-related degenerative diseases.
- Focus on activating key biological resilience pathways.
- Develop orally administered small molecule drugs.
- Target neuromuscular diseases like sarcopenia and Duchenne muscular dystrophy.
- Develop treatments for retinal diseases like dry age-related macular degeneration.
- Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
- Collaborate with research institutions and patient organizations.
How Does BPTS Make Money?
- Develop and patent novel therapeutic compounds.
- Conduct preclinical and clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from agencies like the FDA and EMA.
- Potentially commercialize products directly or through partnerships.
- Generate revenue through product sales, licensing agreements, and research grants.
What Industry Does BPTS Operate In?
Biophytis S.A. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant risks of clinical trial failures. The company focuses on age-related diseases, a growing market due to the increasing global aging population. Competitors include companies like AFMD, ARAV, EIGRQ, FRES and IDRA, which are developing therapies for similar indications. The biotechnology industry is driven by innovation and the ability to bring novel therapies to market, making clinical trial success a critical factor for company valuation and growth.
Who Are BPTS's Key Customers?
- Patients suffering from age-related diseases such as sarcopenia, Duchenne muscular dystrophy, and dry age-related macular degeneration.
- Healthcare providers who prescribe and administer Biophytis's therapeutics.
- Pharmaceutical companies that may partner with Biophytis for drug development and commercialization.
- Research institutions and patient organizations that collaborate with Biophytis on clinical trials and research.
ROE 92%Key Financial Metrics
Return on equity for Biophytis S.A. stands at 92.0%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -0.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.35 means current liabilities exceed short-term assets, a liquidity point worth watching.
Biophytis S.A. (BPTS) Valuation Context
Valued at $2.61M, BPTS is classified as a micro-cap stock. Relative to its peer group, BPTS's quantitative score of 44/100 is below the peer average of 73/100.
Company Profile
Biophytis S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Paris, FR. The company is led by CEO Stanislas Veillet. BPTS has traded publicly since 2021.
F-Score 2/9Financial Health
Biophytis S.A.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -13.38 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Biophytis S.A. revenue of about $33.8M for fiscal 2026, with EPS near $0.00.
BPTS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Novel drug candidates targeting age-related diseases.
- Focus on biological resilience pathways.
- Collaboration with AFM-Telethon.
- Potential for orphan drug designation.
Bear Case
- Clinical-stage company with no approved products.
- Limited financial resources.
- High risk of clinical trial failure.
- Dependence on successful development of Sarconeos and Macuneos.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
BPTS Latest News
No recent news available for BPTS.
BPTS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BPTS.
Price Targets
Wall Street price target analysis for BPTS.
BPTS MoonshotScore
What does this score mean?
The MoonshotScore rates BPTS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Stanislas Veillet
CEO
Stanislas Veillet serves as the CEO of Biophytis S.A. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has held various leadership positions in companies focused on drug development and commercialization. Veillet's expertise spans areas such as strategic planning, business development, and financial management. He has a strong track record of building and scaling biotechnology companies.
Track Record: Under Stanislas Veillet's leadership, Biophytis S.A. has advanced its lead drug candidate, Sarconeos (BIO101), through clinical trials for multiple indications. He has overseen the company's collaboration with AFM-Telethon and secured funding to support research and development activities. Veillet has also focused on expanding the company's pipeline and exploring strategic partnerships.
Biophytis S.A. ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that are held by a U.S. depositary bank. BPTS, as an ADR, allows U.S. investors to trade shares of Biophytis S.A. on U.S. exchanges, simplifying the process of investing in a foreign company. The depositary bank handles currency conversions and other complexities.
- Home Market Ticker: Euronext Paris, France
- ADR Level: 2
- ADR Ratio: 1:1
Biophytis S.A. Healthcare Stock: Key Questions Answered
What does Biophytis S.A. do?
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics for age-related degenerative diseases. Their primary focus is on identifying and activating key biological resilience pathways to combat the effects of aging. The company's lead drug candidate, Sarconeos (BIO101), is being developed for the treatment of neuromuscular diseases like sarcopenia and Duchenne muscular dystrophy, as well as severe respiratory failure associated with COVID-19. They are also developing Macuneos (BIO201) for retinal diseases such as dry age-related macular degeneration.
What do analysts say about BPTS stock?
As a clinical-stage biotechnology company, Biophytis S.A. is subject to significant volatility based on clinical trial outcomes and regulatory milestones. Analyst sentiment is largely dependent on the perceived probability of success for Sarconeos (BIO101) and Macuneos (BIO201). Key valuation metrics include potential peak sales for these drug candidates, discounted by the probability of success and time to market. Given its current market cap of $2.61M, successful clinical trials and regulatory approvals could lead to significant upside, while failures could result in substantial downside risk.
What are the main risks for BPTS?
The primary risks for Biophytis S.A. are related to the inherent uncertainties of drug development. Clinical trial failures for Sarconeos (BIO101) or Macuneos (BIO201) would significantly impact the company's valuation. Regulatory delays or rejection of marketing applications also pose significant risks. Competition from larger, more established pharmaceutical companies with greater resources is another concern. Additionally, the company's limited financial resources and need for additional funding could dilute existing shareholders or hinder development efforts.
What are the key factors to evaluate for BPTS?
Biophytis S.A. (BPTS) holds an AI score of 44/100 (low). Not financial advice.
How frequently does BPTS data refresh on this page?
BPTS prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BPTS's recent stock price performance?
Biophytis S.A. (BPTS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel drug candidates targeting age-related diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BPTS overvalued or undervalued right now?
Valuing Biophytis S.A. (BPTS) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BPTS?
Before investing in Biophytis S.A. (BPTS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide additional insights.